X

Trial Profile

Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Sinovac Biotech

Most Recent Events

21 Sep 2023 Status changed from recruiting to completed.
19 Jan 2023 Results presented in a Sinovac Biotech Media Release.
13 Jan 2023 Results (n=162,691 from two studies NCT04911790 and NCT04992208) assessing Safety of primary immunization using inactivated SARS-CoV-2 vaccine among population aged 3 years and older in a large-scale use published in the Vaccine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com